- Next Steps: Get Started Prescribing Buprenorphine!
- How to Assess and Treat Patients with Comorbid Health Issues
- How to Conduct Buprenorphine Induction
- How to Establish and Manage a Buprenorphine Practice
- How to Manage Challenging Patients
- How to Comply with Rules, Regulations, and Recordkeeping
- Federal (DEA) Recordkeeping Requirements for Buprenorphine Treatment
- Federal Guidelines for Dispensing Buprenorphine Tablets in the Office
- Guidelines for Writing a Prescription for Buprenorphine
- DEA Oversight and Audits of Buprenorphine Treatment Programs
- Patient Privacy Issues for Buprenorphine Treatment
- Medical Recordkeeping Guidelines for Substance Abuse Patients
- How to Understand Insurance and Billing Issues
- How to Screen for Substance Abuse
- How to Refer Patients to an Addiction Specialist
- Review: What is Buprenorphine?
When buprenorphine was first approved by the FDA in October 2003, few pharmacies consistently kept the medication in stock and thus many physicians kept a supply of tablets on hand and dispensed them from their office. In-office buprenorphine dispensing is still a legal practice under DATA 2000.
However, physicians who wish to dispense buprenorphine from their office must adhere to strict federal recordkeeping guidelines.
The following records must be maintained for 2 years:
- Inventories, including amounts of buprenorphine received and amounts dispensed
- Reports of theft or loss
- Destruction of controlled drugs
- Records of dispensing
Additionally, the buprenorphine tablets must be stored in a secure, locked cabinet. Note that physicians who have their patients get their prescription filled at a pharmacy and return to the office for induction are NOT subject to the same recordkeeping guidelines as physicians who store and dispense the tablets in-office.
This page links to the full text, summary, and physician waiver requirements under DATA 2000.
Substance Abuse and Mental Health Services Administration (SAMHSA)
This log can be used to keep track of office inventories of buprenorphine medication.
California Society of Addiction Medicine (CSAM)